Phase I/II radioimmunotherapy with high-dose 90Y-labeled humanized MN-14 [labetuzumab Y-90] in advanced ovarian cancer using autologous peripheral blood stem cell rescue (PBSCR) to control myelotoxicity
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2011
At a glance
- Drugs Labetuzumab Y-90 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2005 New trial record.